[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"benign-liver-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:benign-liver-tumor":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100553466","real-world-evaluation-of-the-histosonics-edison-system-for-treatment-of-liver-tumors-across-multidisciplinary-users-boombox-master-study-100553466",false,"NCT06486454","Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)","Inclusion Criteria:\n\n1. Subject is ≥22 years of age\n2. Subject has signed the Ethics Committee (EC), or Institutional Review Board (IRB) approved study Informed Consent Form (ICF) prior to any study related tests\u002Fprocedures and is willing to comply with study procedures and required follow-up assessments\n3. Subject's liver tumor(s) can be partially or completely treated with histotripsy\n\nExclusion Criteria:\n\n1. Subject is pregnant or planning to become pregnant or nursing (lactating) during the study period\n2. Subject is enrolled in an interventional HistoSonics-sponsored trial\n3. Subject has a concurrent condition that, in the investigator's opinion, could jeopardize the safety of the subject or compliance with the protocol","ALL","22 Years",{"count":18,"type":19},5000,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure. Sub-studies to the BOOMBOX: Master Study will investigate specific populations and\u002For clinical questions with more stringent enrollment criteria, standardized testing criteria, and\u002For follow-up schedule. Any participant enrolled in the BOOMBOX: Master Study that also qualifies for a sub-study may enroll in the sub-study in parallel; sub-studies will be described in separate sub-study protocols. The BOOMBOX: Master Study will collect information about participants before, during, and after the histotripsy treatment procedure. All participants will be followed per standard clinical follow-up based on each site's clinical practice for up to 5 years after the initial histotripsy procedure or until completion of their follow-up in a sub-study, whichever is longer.",[23,24,25,26,27],"Liver Neoplasms","Primary Liver Cancer","Secondary Liver Cancer","Tumor Liver","Benign Liver Tumor",[29],"histotripsy","RECRUITING","2026-06-01",{"date":33,"type":34},"2026-06-03","ACTUAL",{"date":36,"type":34},"2024-10-14",{"date":38,"type":19},"2031-11",{"name":40,"class":41},"HistoSonics, Inc.","INDUSTRY",30,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100585642","stroke-volume-variation-versus-central-venous-pressure-guidance-for-reducing-perioperative-blood-loss-during-open-liver-resection-100585642","NCT06905015","Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver Resection","Comparison the Effectiveness of Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver Resection: A Prospective, Double-Blinded, Noninferiority, Randomized Controlled Study","Inclusion Criteria:\n\n* All genders, age 18 to 70 years old\n* American Society of Anesthesiologists (ASA) physical status classification of I-III\n* The patients who scheduled in elective open liver resection and diagnosed Hepatocellular Carcinoma, Cholangiocarcinoma, Liver metastasis, and Benign malignant tumor.\n\nExclusion Criteria:\n\n* Pregnancy\n* Active cardiac conditions (unstable coronary syndromes, decompensated heart failure, significant arrhythmias, severe valvular disease, active coronary artery disease within 6 months prior surgery)\n* History of significant cerebrovascular disease (Patients with clinically significant stroke\u002FCVA within 6 months prior surgery, severe carotid stenosis)\n* Renal dysfunction (GFR \\\u003C 60 ml\u002Fmin\u002F1.73 m²)\n* Abnormal coagulation parameters (INR \\>1.5 not on warfarin and\u002For platelet count \\\u003C100,000)\n* Preoperative autologous blood donation\n* Tumor size \\> 10 cm.\n* Previous liver resection\n\nWithdrawal criteria:\n\n* Unresectable tumor\n* Persistent intraoperative hypotension that cannot be corrected with vasopressors.\n* Cardiac arrest during operation\n* Low central venous pressure (CVP \\\u003C 5 mmHg) or high stroke volume variation (SVV \\>13%) cannot be achieved before and during liver parenchymal transection.","20 Years","70 Years",{"count":53,"type":19},74,"INTERVENTIONAL",[56],"NA","Liver resection is a major surgery that can be associated with significant intraoperative blood loss and blood transfusion. Among high-volume centers, median intraoperative blood loss ranges between 300-800 ml. Excessive blood loss is a strong independent predictor of worsened postoperative outcomes, increasing morbidity and mortality rates by 20%-35%. Additionally, perioperative allogeneic blood transfusions are associated with deleterious outcomes, including tumor recurrence and increased rates of complications and death.\n\nThe liver is a highly vascular organ with minimal vascular resistance, receiving up to 25% of cardiac output and pooling 20% of the splanchnic blood. Hepatic veins are a common source of venous hemorrhage. The pressure in the hepatic veins is directly correlated with the pressure in the vena cava and reducing cardiac preload results in decreased hepatic vein congestion. Therefore, low central venous pressure anesthesia (typically below 5 mmHg) can reduce the pressure gradient for retrograde venous bleeding, facilitate the outflow of blood from hepatic veins, and decrease blood volume and pressure in the liver. This anesthetic method is the standard technique to minimize blood loss during liver resection.\n\nCentral venous pressure was the static parameter used to indicate the right ventricular end-diastolic volume index (RVEDI) and was believed to be correlated with volume status. Despite this, central venous pressure did not reliably predict preload responsiveness due to the curvilinear shape of the ventricular pressure-volume curve, which indicates a poor relationship between ventricular filling pressure and volume. Additionally, the placement of a central venous catheter could lead to serious complications such as arterial cannulation, pneumothorax, and infection.\n\nArterial waveform analysis is dynamic hemodynamic monitoring based on the interaction between the heart and lungs in patients with mechanical ventilation. Stroke volume variation (SVV) is one aspect of arterial pressure waveform analysis and is a less invasive alternative technique for guiding preload status and fluid management in patients undergoing major abdominal surgery.\n\nIn liver resection, several anesthetic methods are used to achieve low central venous pressure (CVP \\\u003C 5 mmHg) during the liver parenchymal dissection phase. These methods include intraoperative volume restriction, administration of venodilators or vasodilators, the use of forced diuresis with furosemide, and the implementation of hypovolemic phlebotomy. As mentioned, central venous pressure is a static hemodynamic monitoring parameter and poorly correlates with volume status. Recently, stroke volume variation has been recognized as a good parameter to predict volume status and fluid responsiveness in patients undergoing liver resection. However, no previous publications have studied the efficacy of stroke volume variation monitoring compared with central venous pressure monitoring to reduce perioperative blood loss during open liver resection.\n\nThe study aimed to compare the efficacy of maintaining high stroke volume variation versus low central venous pressure in reducing perioperative blood loss during the liver transection phase in open liver resection.",[59,60,24,61,27],"Liver Tumor; Surgery","Primary Liver Tumor, Metastatic Liver","Liver Resection",[63,64,65,66],"Stroke volume variation","central venous pressure","open liver resection","blood loss","2025-03-25",{"date":69,"type":34},"2025-04-01",{"date":71,"type":34},"2024-11-25",{"date":73,"type":19},"2028-06-30",{"name":75,"class":76},"Warangkana Lapisatepun","OTHER",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":20,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100582987","hepatic-excision-and-ablation-log-100582987","NCT06870461","Hepatic Excision and Ablation Log","HEAL","Inclusion Criteria:\n\n* Both benign and malignant liver lesions are included\n\nExclusion Criteria:\n\n\\- Intervention performed solely for liver biopsy, without any subsequent surgical resection or ablation.","18 Years",{"count":87,"type":19},1000,"10 Years","This study aims to establish a registry for liver surgery and ablation procedures to improve patient care, advance research, and enhance surgical quality. The registry will collect pseudonymized data on patient demographics, disease characteristics, procedural details, and outcomes.",[91,27],"Malignant Liver Tumor","NOT_YET_RECRUITING","2025-03-05",{"date":95,"type":34},"2025-03-11",{"date":69,"type":19},{"date":98,"type":19},"2040-01",{"name":100,"class":76},"University Hospital, Antwerp"]